The Preclinical Tomography System Market size is expected to exceed USD 628.45 million by 2032, from USD 412.44 million in 2023, delivering a CAGR of 7.8% through the forecast period.
The market growth is driven by growing demand for clinical imaging techniques for disease diagnosis & drug development, a rise in technological advancements in molecular imaging, along with substantial preclinical research funding by private and public organizations.
The preclinical tomography system aids in the visualization of living animals through high-resolution three-dimensional image generation for research purposes, such as disease diagnosis and drug development. The technological advancement of preclinical imaging has enabled the study of diseases at the molecular level. This has further aided in the fast transfer of preclinical studies on animal models to clinical investigation in humans.
Request a Sample@ https://www.qyresearchmedical.com/sample/119484
Cancers, neurological disorders, cardiovascular diseases, and autoimmune diseases are some of the key diseases that areas targeted with preclinical imaging. Cancer accounts for 70% of the preclinical imaging usage, followed by autoimmune diseases and neurological disorders, accounting for 36% and 32%, respectively. Globally, the total number of new cases of cancer rose to 18.1 million, while the death toll was at 9.6 million in 2018. The rising prevalence of cancer and neurological disorders will bolster preclinical tomography market share through 2032. Moreover, the introduction of next-generation SPECT cameras with CZT (cadmium zinc telluride) detectors can lower patient radiation dose, shorten examination time, thereby fuelling product demand over the forecast period.
In terms of product type, the preclinical tomography market share is segmented into CT, PET, & SPECT, and Composite System. The PET (Positron emission tomography) segment is estimated to contribute significantly to the global revenue share on account of high product adoption for diagnostic imaging of metabolic function. This technology has undergone significant evolution, with most PET scanners integrated with computed tomography scanners.
The CT (computed tomography) segment is expected to witness substantial growth as it enables direct imaging and differentiation of soft tissue structures of lung tissue, fat, and liver tissue. Computed tomography finds extensive application in observing tumors, metastasis for interventional work like CT guided biopsy & minimally invasive therapy. The technique is excellent for planning cancer radiotherapy and to determine how a tumor is responding to treatment. In 2013, the American Cancer Society also gave approval for LDCT (low-dose computed tomography) for lung cancer screening.
The SPECT (single-photon emission computed tomography) segment is set to witness significant growth over the analysis period due to extensive usage in the diagnosis of seizures, stress fractures, stroke, tumors in the spine, and infections. The SPECT scan enables the observation of blood flow to tissues and organs. It is proven that SPECT might be more sensitive to brain injury than either CT scan or MRI because it can precisely detect reduced blood flow to injured sites. It is also used for presurgical evaluation of medically uncontrolled seizures.
In the regional landscape, North America is estimated to be a major regional ground for the preclinical tomography market, followed by Europe and the Asia Pacific. Europe is anticipated to hold the second largest of the market share due to the rise in the number of research and development activities in the medical field. The Asia Pacific is likely to register a faster growth through 2032 due to the massive patient pool and rise in clinical and preclinical research activities, supported by government funding in the region.
Key players operating in the global preclinical tomography market are PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), and FUJIFILM Holdings Corporation (Japan), Mediso Ltd. (Hungary), MILabs B.V. (Netherlands), MR Solutions (U.K.), Scanco Medical (U.K.), LI-COR Biosciences (U.S.), Aspect Imaging (Israel), TriFoil Imaging (U.S.), Miltenyi Biotech GmbH (Germany), and Sedecal MILabs (Spain), among others.
On 30th April 2023, Canon Medical Systems Corporation, a Japan-based medical equipment company, introduced a deployable CT (computed tomography) system with a rapid decontamination solution in a bid to enhance the safety of healthcare providers and patients during the COVID-19 pandemic.
On 12th June 2018, Bruker Corporation, a US-based manufacturer of scientific instruments for molecular & materials research, launched a multiscale X-ray nano-CT system, SKYSCAN™ 2214, comprising a detector geometry and innovative X-ray source that produces sharper images with high precision.
Segments covered in this market study
This report about the global preclinical tomography system market forecasts revenue growth at the global, regional, and country-level, provides an analysis of the industry trends in each of the sub-segments from 2023 to 2032. For the purpose of this study, the market is segmented on the basis of type, application, and region:
By Type (Revenue in USD Million; 2023–2032)
- CT, PET, & SPECT
- Composite System
By Application (Revenue in USD Million; 2023–2032)
- Research Institute
By Region (Revenue in USD Million; 2023–2032)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119484/1500
You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/